Charnaya Olga, Ishaque Tanveen, Hallett Andrew, Morris Gerald P, Coppage Myra, Schmitz John L, Timofeeva Olga, Lázár-Molnár Eszter, Zhang Aiwen, Krummey Scott, Hidalgo Luis, Segev Dorry L, Tambur Anat R, Massie Allan B
Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD.
Center for Surgical and Transplant Applied Research, NYU Langone Health, New York, NY.
Transplantation. 2025 Apr 1;109(4):720-728. doi: 10.1097/TP.0000000000005198. Epub 2024 Sep 5.
HLA-DQ mismatch has been identified as a predictor of de novo donor-specific HLA antibody formation and antibody-mediated rejection. There are insufficient data to guide the incorporation of DQ mismatch into organ allocation decisions.
We used a retrospective longitudinal cohort of adult living donor kidney transplant recipients from 11 centers across the United States for whom high-resolution class II typing was available. HLA-DQαβ heterodimer allele mismatch was quantified for all donor-recipient pairs, and outcome data were obtained through linkage with the Scientific Registry of Transplant Recipients.
We studied 3916 donor-recipient pairs. Recipient characteristics were notable for a median age of 51 (38-61) y, primarily unsensitized, with 74.5% of the cohort having 0% calculated panel-reactive antibody, and 60.4% with private insurance, for a median follow-up time of 5.86 y. We found that the HLA-DQαβ allele and HLA-DR antigen mismatch were each individually associated with an increased hazard of all-cause graft failure (adjusted hazard ratio [aHR] DQ = 1.03 1.14 1.28 ; aHR DR = 1.03 1.15 1.328 ), death-censored graft failure (aHR DQ = 1.01 1.19 1.40 ; aHR DR = 0.099 1.18 1.39 ), and rejection. Having 2 HLA-DQαβ allele mismatches further increased the hazard of rejection even when controlling for HLA-DR mismatch (aHR 1.03 1.68 2.74 ).
HLA-DQαβ allele mismatch predicted allograft rejection even when controlling for HLA-DR antigen mismatch and were both independently associated with increased risk of graft failure or rejection in adult living kidney transplant recipients. Given the strong burden of disease arising from the HLA-DQ antibody formation, we suggest that HLA-DQαβ should be prioritized over HLA-DR in donor selection.
HLA - DQ错配已被确定为新发供者特异性HLA抗体形成和抗体介导排斥反应的预测指标。目前尚无足够数据指导将DQ错配纳入器官分配决策。
我们使用了来自美国11个中心的成年活体供肾移植受者的回顾性纵向队列,这些受者有高分辨率的II类分型数据。对所有供受者对进行HLA - DQαβ异二聚体等位基因错配定量,并通过与移植受者科学注册系统的链接获取结局数据。
我们研究了3916对供受者对。受者特征值得注意的是,中位年龄为51(38 - 61)岁,主要为未致敏,队列中74.5%的受者计算得出的群体反应性抗体为0%,60.4%有私人保险,中位随访时间为5.86年。我们发现HLA - DQαβ等位基因错配和HLA - DR抗原错配均分别与全因移植失败风险增加相关(校正风险比[aHR] DQ = 1.03、1.14、1.28;aHR DR = 1.03、1.15、1.328),死亡删失移植失败(aHR DQ = 1.01、1.19、1.40;aHR DR = 0.099、1.18、1.39)以及排斥反应。即使在控制HLA - DR错配的情况下,存在2个HLA - DQαβ等位基因错配仍会进一步增加排斥反应风险(aHR 1.03、1.68、2.74)。
即使在控制HLA - DR抗原错配的情况下,HLA - DQαβ等位基因错配仍可预测同种异体移植排斥反应,且二者均独立与成年活体肾移植受者移植失败或排斥反应风险增加相关。鉴于HLA - DQ抗体形成带来的沉重疾病负担,我们建议在供者选择中,HLA - DQαβ应优先于HLA - DR考虑。